Back to top
more

Akebia Therapeutics (AKBA)

(Delayed Data from NSDQ)

$1.42 USD

1.42
3,758,847

+0.11 (8.40%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $1.42 0.00 (0.00%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (162 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Encompass Health Continues to Strengthen Presence in Florida

by Zacks Equity Research

Encompass Health (EHC) intends to offer improved health outcomes through plans to construct a new hospital in Florida, where it already boasts of a strong base.

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AKBA) Outperforming Other Medical Stocks This Year?

Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).

How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 25.40% and 14.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

Akebia Therapeutics (AKBA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -35.56% and -27.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) Stock

by Zacks Equity Research

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 24.32% and -2.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -4.76% and -13.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Expands Vadadustat Licensing Deal With Vifor Pharma

by Zacks Equity Research

Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.

Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 40.26% and 33.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error

by Zacks Equity Research

Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.

    Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

    by Zacks Equity Research

    Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.